Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 4/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.38 |
| ▸ | CCR3 | P51677 | 2/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
| ▸ | F2R | P25116 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4405461 | 0.67 | CACNB4 (0.55) | ENPP2MCHR1F2R | |
| SCHEMBL4399843 | 0.67 | CACNB4 (0.50) | ENPP2TP53MCHR1SMN1; SMN2ALDH1A1 | |
| SCHEMBL6705838 | 0.60 | CTSS (0.43) | SMN1; SMN2 | |
| SCHEMBL4069435 | 0.60 | EPHX2 (0.60) | EPHX2SMN1; SMN2 | |
| SCHEMBL4798052 | 0.60 | CTSS (0.38) | SMN1; SMN2 | |
| SCHEMBL28573759 | 0.60 | PPARG (0.43) | TP53EPHX2ALDH1A1KDM4E | |
| SCHEMBL9035239 | 0.59 | KDM4E (0.72) | MCHR1SMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL3017456 | 0.59 | RAB9A (0.40) | SMN1; SMN2 | |
| SCHEMBL2927563 | 0.58 | MCHR1 (0.75) | MCHR1CCR3HTR2CKDM4EALOX12 | |
| SCHEMBL5204675 | 0.58 | MCHR1 (0.67) | MCHR1SMN1; SMN2HTR2CALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7629319-B2 | Heteroaryl peptidomimetics as thrombin receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-12-08 | — | — | US | disclosed |
| US-7618945-B2 | Heteroaryl peptidomimetics as thrombin receptor antagonists | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-11-17 | — | — | US | disclosed |
| US-20060009396-A1 | Novel heteroaryl peptidomimetics as thrombin receptor antagonists | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-01-12 | — | — | US | disclosed |
| US-20040138141-A1 | Novel heteroaryl peptidomimetics as thrombin receptor antagonists | JANSSEN PHARMACEUTICA, NV (BE) | 2004-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060009396-A1 | Novel heteroaryl peptidomimetics as thrombin receptor antagonists | PTAFR, F2R, F2RL1 | ENPP2 233/4885TP53 2160/4885MCHR1 997/4885 |
| US-20040138141-A1 | Novel heteroaryl peptidomimetics as thrombin receptor antagonists | PTAFR, F2R, F2RL1 | ENPP2 233/4885TP53 2160/4885MCHR1 997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.